The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Ionis Pharmaceuticals Inc shares valued at $109,440 were purchased by Monia Brett P on Jul 30 ’25. At $45.00 per share, Monia Brett P acquired 2,432 shares.
Also, Monia Brett P sold 1,160 shares, netting a total of over 48,416 in proceeds. Following the sale of shares at $41.74 each, the insider now holds 179,820 shares.
Before that, Hayden Michael R had added 15,000 shares to its account. In a trade valued at $477,900, the Director bought Ionis Pharmaceuticals Inc shares for $31.86 each. Upon closing the transaction, the insider’s holdings increased to 15,000 shares, worth approximately $2.16 million.
As published in a research note from Morgan Stanley on July 31, 2025, Ionis Pharmaceuticals Inc [IONS] has been rated up from an Equal-weight to an Overweight and the price target has been revised to $62. Analysts at Barclays upgraded the stock from ‘”an Equal weight”‘ to ‘”an Overweight”‘ outlook in a report released in early July. As of April 07, 2025, H.C. Wainwright has initiated its “Buy” rating for IONS. Earlier on March 31, 2025, Redburn Atlantic initiated its rating. Their recommendation was “a Neutral” for IONS stock.
Analyzing IONS Stock Performance
On last trading session, Ionis Pharmaceuticals Inc [NASDAQ: IONS] plunged -0.90% to $42.98. The stock’s lowest price that day was $42.325, but it reached a high of $44.97 in the same session. During the last five days, there has been a surge of approximately 1.97%. Over the course of the year, Ionis Pharmaceuticals Inc shares have dropped approximately -14.45%. Shares of the company reached a 52-week high of $45.66 on 07/30/25 and a 52-week low of $23.95 on 04/09/25.
Support And Resistance Levels for Ionis Pharmaceuticals Inc (IONS)
According to the 24-hour chart, there is a support level at 41.88, which, if violated, would cause prices to drop to 40.77. In the upper region, resistance lies at 44.53. The next price resistance is at 46.08. RSI (Relative Strength Index) is 61.12 on the 14-day chart, showing neutral technical sentiment.
Is Ionis Pharmaceuticals Inc subject to short interest?
Stocks of Ionis Pharmaceuticals Inc saw a sharp steep in short interest on 2025-07-15 dropping by -1.34 million shares to 12.89 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 14.23 million shares. A decline of -10.37% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.13 of the overall float, the days-to-cover ratio (short ratio) decline to 6.13.
Which companies own the most shares of Ionis Pharmaceuticals Inc (IONS)?
In terms of Ionis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 63.5 in the next 12 months, up nearly 46.41% from the previous closing price of $43.37. Analysts anticipate Ionis Pharmaceuticals Inc stock to reach 65 by 2025, with the lowest price target being 62. In spite of this, 14 analysts ranked Ionis Pharmaceuticals Inc stock as Buy at the end of 2025. On August 02, 2024, BMO Capital Markets assigned a price target of “a Market perform” to the stock and downgraded coverage with a $60.
